Rhythm Pharmaceuticals/$RYTM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Ticker

$RYTM
Sector
Primary listing

Employees

283

RYTM Metrics

BasicAdvanced
$6.8B
-
-$3.02
2.39
-

What the Analysts think about RYTM

Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.

Bulls say / Bears say

Global sales of IMCIVREE (setmelanotide) grew 29% sequentially to $48.5 million in Q2 2025, driven by strong uptake in Bardet-Biedl syndrome, with U.S. revenue up 31% quarter-on-quarter to $32.0 million (GlobeNewswire​).
Rhythm is on track to submit U.S. and EU filings for setmelanotide in acquired hypothalamic obesity in Q3 2025, positioning the company for a potential label expansion into a new rare disease indication (GlobeNewswire​).
The Phase 2 trial of oral MC4R agonist bivamelagon met its primary endpoint with BMI reductions of 9.3% at the 600 mg dose (p=0.0004) and 7.7% at 400 mg (p=0.0002), and Phase 3 TRANSCEND data showed a –19.8% placebo-adjusted BMI reduction in acquired hypothalamic obesity, underscoring strong clinical differentiation (GlobeNewswire​).
Rhythm’s net loss widened to $48.0 million in Q2 2025, or $0.75 per share, compared with a $33.6 million loss ($0.55 per share) a year earlier, reflecting increased expense pressure (GlobeNewswire​).
Cash, cash equivalents and short-term investments fell to $291.0 million as of June 30, 2025, down from $320.6 million at year-end 2024, excluding the $189.2 million raised in July, underscoring ongoing cash burn from R&D and SG&A (GlobeNewswire​).
R&D expenses rose to $42.3 million and SG&A to $45.9 million in Q2 2025, increases that outpaced revenue growth and may pressure margins until new indications broaden the commercial base (GlobeNewswire​).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

RYTM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RYTM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RYTM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs